Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Jaguar Health Subsidiary Napo Pharmaceuticals Launches New Website for Mytesi, Napo’s FDA-Approved, First-in-Class Anti-Secretory Human Prescription Drug

Jaguar Health,Inc.
Posted on: 01 Nov 17

Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar), a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis, announced today that its wholly-owned subsidiary, Napo Pharmaceuticals, Inc. (Napo), has launched a significantly enhanced version of Mytesi.com, the website for Mytesi® (crofelemer), Napo’s first-in-class anti-secretory human prescription drug.

Mytesi® is the first and only antidiarrheal approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The new Mytesi.com website is designed to provide both people living with HIV or AIDS (PLWHA), and clinicians and other healthcare professionals with information about HIV-related diarrhea and Mytesi®. For PLWHA, the site provides product information in consumer-friendly language, tools to help them facilitate a conversation about HIV-related diarrhea with their physician—including a symptom checklist and a diarrhea symptom questionnaire that can be printed and provided to the doctor—and information about the Mytesi® Copay Savings Card.

A new “Healthcare Professional” area on the site provides Mytesi®-related scientific and clinical trial data for HIV physicians as well as gastroenterologists—many of whom see large numbers of PLWHA.

“As someone living with HIV, the internet is my go-to for anything related to HIV. For newly diagnosed patients, having this information online, presented in a way that is consumable by a non-medical professional, is even more important, as the web is typically the first place one goes to when needing more information. A lot of people feel more comfortable searching on their computer verses talking to a doctor upfront, so it’s critical that the right information is out there, available for anyone who's searching for it,” stated David Duran, a nationally recognized HIV advocate and writer who contributes to a number of leading HIV-focused publications.

Mytesi® works by normalizing water flow in the intestines, which is different from other antidiarrheals, and, because Mytesi® is not absorbed into the blood stream, it has few side effects and no drug-drug interactions. Mytesi® is widely available, and people living with HIV/AIDS who are tired of planning their life around diarrhea can ask their provider for a prescription for Mytesi®.

About Mytesi ®

Mytesi® (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

More information and complete Prescribing Information are available at Mytesi.com. Crofelemer, the active ingredient in Mytesi®, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

About Napo Pharmaceuticals, Inc.

San Francisco-based Napo Pharmaceuticals, Inc. (Napo), focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Napo is a wholly-owned subsidiary of Jaguar Health, Inc., a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis.

For more information about Napo, visit napopharma.com. For more information about Jaguar, please visit jaguar.health.

Jaguar-JAGX

View source version on businesswire.com: http://www.businesswire.com/news/home/20171101005930/en/

Business Wire
www.businesswire.com

Last updated on: 01/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.